Cisplatin-associated ototoxicity amongst patients receiving cancer chemotherapy and the feasibility of an audiological monitoring program

QUESTIONNAIRE FOR PARTICIPANTS WITH CANCER POST MONITORING PROGRAM

Dear Participant

We are delighted that you have agreed to participate and would like to thank you sincerely, for the information from this study can be used to help us understand the complexities associated with chemotherapy. The information that you provide will be treated with the strictest of confidence and please do not hesitate to ask us any questions that you may have during the course of the study. Contact details are reflected on the information and consent document.

INSTRUCTIONS

1. Please mark the appropriate answer to each question with an X, and give further detail if necessary.

2. Please answer all questions.
1. Did you receive information about the effects of the chemotherapy medication before commencing with treatment?  
   Yes  
   No

2. If so, who provided you with information?
   Nurse  
   Oncologist  
   Pharmacist  
   Audiologist

3. Who referred you for the audiological monitoring?
   Nurse  
   Oncologist  
   Pharmacist  
   Audiologist

4. Were the audiological evaluations conducted on the same day as your chemotherapy?
   Yes  
   No  
   Sometimes

5. Do you feel that the duration of the audiological testing was too long?
   Yes  
   No

6. Were the results of the audiological evaluations clearly explained to you?
   Yes  
   No  
   Sometimes

7. Which of the following recommendations were made?
   Hearing aid evaluation  
   Counselling  
   Tinnitus management

8. Did you follow-up on any of the above recommendations made?
   Yes  
   No  
   Sometimes

9. Do you feel that the monitoring of your hearing during chemotherapy was beneficial?
   Yes  
   No  
   Don’t know